Osteoblastogenesis and tumor growth in myeloma
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Myeloma is associated with suppression of osteoblastogenesis, consequentially resulting in increased osteoclast activity and induction of typical osteolytic bone disease. The molecular mechanisms by which myeloma cells suppress osteoblastogenesis and the consequences of increased osteoblast activity on myeloma cell growth have been partially delineated only recently. Reduced osteoblastogenesis is a consequence of abnormal properties and impaired osteogenic potential of osteoprogenitor cells from myeloma patients and is also the result of production of multiple osteoblastogenesis inhibitors by myeloma cells and by microenvironmental cells within the myelomatous bone. Nevertheless, novel osteoblast-activating agents (e.g. proteasome inhibitor bortezomib) are capable of inducing bone formation in myeloma animal models and clinically. These agents induce increased osteoblast activity, often coupled with a concomitant reduction in osteoclastogenesis, that is strongly associated with reduced myeloma tumor burden. In vitro, osteoblasts, in contrast to osteoclasts, attenuate the growth of myeloma cells from a large subset of patients; potential molecular mechanisms are discussed. These studies suggest that myeloma cells suppress osteoblastogenesis to their advantage and that increased osteoblast activity is a promising approach to treat myeloma bone disease and simultaneously control myeloma development and progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“The ubiquitin–proteasome pathway plays a critical role in regulating growth and survival of myeloma cells, providing strong rationale for proteasome targeting and the successful introduction of bortezomib into clinical management of myeloma [67].”
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753 · cited 1×
“These patients are often treated with the glucocorticoid dexamethasone, a clinical frontline drug known to reduce the life span of osteoblasts and osteocytes and to enhance survival of osteoclasts [84,85].”
Canonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass, D. A., Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.017 · Cited by 1,558
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475 · cited 1×
“Patients with monoclonal gammopathy of undetermined significance (MGUS), a benign disease with an annual conversion rate of 1% to overt myeloma, do not have typical osteolytic lesions seen in patients with active MM [5].”
Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127 · cited 1×
“In light of a recent prospective study suggesting that an asymptomatic MGUS stage consistently preceded MM [7], these findings suggest that”
Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis
Zhao, C., Irie, N., Takada, Y., Shimoda, K., Miyamoto, T., Nishiwaki, T., Suda, T., & Matsuo, K. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.012 · Cited by 777
The cell biology of bone metabolism
Datta, H. K., Ng, W. F., Walker, J. A., Tuck, S. P., & Varanasi, S. S. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.048868 · Cited by 614 · cited 1×
“The coupling of osteoclastic bone resorption to osteoblastic bone formation is tightly controlled by communication between osteogenic cells and osteoclasts via cell surface and systemic factors [1].”
Pathogenesis of myeloma bone disease
Roodman, G. D. (2009) · Leukemia · doi:10.1038/leu.2008.336 · Cited by 398
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma
Corre, J., Mahtouk, K., Attal, M., Gadelorge, M., Huynh, A., Fleury-Cappellesso, S., Danho, C., Laharrague, P., Klein, B., Rème, T., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404621 · Cited by 328
Yaccoby, S., Pearse, R. N., Johnson, C. L., Barlogie, B., Choi, Y., & Epstein, J. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03257.x · Cited by 305
Self-citation
Cited by
Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma
Liu, H., Liu, Z., Du, J., He, J., Lin, P., Amini, B., Starbuck, M. W., Novane, N., Shah, J. J., Davis, R. E., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8949 · Cited by 74
The osteoblastic niche in the context of multiple myeloma
Toscani, D., Bolzoni, M., Accardi, F., Aversa, F., & Giuliani, N. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12578 · Cited by 52
Fairfield, H., Costa, S., Falank, C., Farrell, M., Murphy, C. S., D’Amico, A., Driscoll, H., & Reagan, M. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.584683 · Cited by 42
García-Sánchez, D., González-González, A., Alfonso-Fernández, A., Del Dujo-Gutiérrez, M., & Pérez-Campo, F. M. (2023) · World Journal of Stem Cells · doi:10.4252/wjsc.v15.i5.421 · Cited by 32
Metadata
- Authors
- Yaccoby, S.
- Venue
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Published
- 2009-12-29
- Volume
- 51
- Issue
- 2
- Pages
- 213-220
- ISSN
- 1026-8022 (ISSN-L)
- 1042-8194
- 1029-2403
- OpenAlex
- W2104958967
- Cited by
- 52
- References
- 14
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Osteoblastogenesis and tumor growth in myeloma. https://app.cochat.ai/papers/10.3109/10428190903503438
- The paper
- Yaccoby, S. (2010). Osteoblastogenesis and tumor growth in myeloma. Leukemia & Lymphoma. https://doi.org/10.3109/10428190903503438
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.